Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Pharmacology of grapiprant, a novel EP4 antagonist: receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs.

Nagahisa A, Okumura T.

J Vet Pharmacol Ther. 2017 Jun;40(3):285-292. doi: 10.1111/jvp.12349. Epub 2016 Sep 6.

PMID:
27597397
2.

Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides and related compounds.

Bookser BC, Ugarkar BG, Matelich MC, Lemus RH, Allan M, Tsuchiya M, Nakane M, Nagahisa A, Wiesner JB, Erion MD.

J Med Chem. 2005 Dec 1;48(24):7808-20.

PMID:
16302820
3.

Histological study of granulated metrial gland (GMG) cells in beige (DA-bg/bg) rats.

Hondo E, Kokubu K, Nagahisa A, Nakamuta N, Ozaki K, Sagara E, Kiso Y.

J Reprod Dev. 2005 Dec;51(6):799-803. Epub 2005 Oct 7.

4.

Adenosine kinase inhibitors. 5. Synthesis, enzyme inhibition, and analgesic activity of diaryl-erythro-furanosyltubercidin analogues.

Boyer SH, Ugarkar BG, Solbach J, Kopcho J, Matelich MC, Ollis K, Gomez-Galeno JE, Mendonca R, Tsuchiya M, Nagahisa A, Nakane M, Wiesner JB, Erion MD.

J Med Chem. 2005 Oct 6;48(20):6430-41.

PMID:
16190769
5.

Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret.

Tsuchiya M, Fujiwara Y, Kanai Y, Mizutani M, Shimada K, Suga O, Ueda S, Watson JW, Nagahisa A.

Pharmacology. 2002 Nov;66(3):144-52.

PMID:
12372904
6.

Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors.

Minami M, Endo T, Yokota H, Ogawa T, Nemoto M, Hamaue N, Hirafuji M, Yoshioka M, Nagahisa A, Andrews PL.

Eur J Pharmacol. 2001 Oct 5;428(2):215-20.

PMID:
11675038
7.

Induction of hepatic microsomal drug-metabolizing enzymes by inhibitors of 5-lipoxygenase (5-LO): studies in rats and 5-LO knockout mice.

Beierschmitt WP, McNeish JD, Griffiths RJ, Nagahisa A, Nakane M, Amacher DE.

Toxicol Sci. 2001 Sep;63(1):15-21.

PMID:
11509739
8.

Highly potent nociceptin analog containing the Arg-Lys triple repeat.

Okada K, Sujaku T, Chuman Y, Nakashima R, Nose T, Costa T, Yamada Y, Yokoyama M, Nagahisa A, Shimohigashi Y.

Biochem Biophys Res Commun. 2000 Nov 19;278(2):493-8.

PMID:
11097863
9.

Erinacine E as a kappa opioid receptor agonist and its new analogs from a basidiomycete, Hericium ramosum.

Saito T, Aoki F, Hirai H, Inagaki T, Matsunaga Y, Sakakibara T, Sakemi S, Suzuki Y, Watanabe S, Suga O, Sujaku T, Smogowicz AA, Truesdell SJ, Wong JW, Nagahisa A, Kojima Y, Kojima N.

J Antibiot (Tokyo). 1998 Nov;51(11):983-90.

10.

Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist.

Rosen TJ, Coffman KJ, McLean S, Crawford RT, Bryce DK, Gohda Y, Tsuchiya M, Nagahisa A, Nakane M, Lowe JA 3rd.

Bioorg Med Chem Lett. 1998 Feb 3;8(3):281-4.

PMID:
9871670
11.

Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist.

Taniguchi K, Shinjo K, Mizutani M, Shimada K, Ishikawa T, Menniti FS, Nagahisa A.

Br J Pharmacol. 1997 Nov;122(5):809-12.

12.

Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.

Carty TJ, Sweeney FJ, Griffiths RJ, Eskra JD, Ernest MJ, Pillar JS, Cheng JD, Loose LD, Joseph PA, Pazoles PP, Moore PF, Nagahisa A, Murase S, Kadin SB.

Inflamm Res. 1997 May;46(5):168-79.

PMID:
9197987
13.

Efficacy of a selective histamine H2 receptor agonist, dimaprit, in experimental models of endotoxin shock and hepatitis in mice.

Nakamura T, Ueno Y, Goda Y, Nakamura A, Shinjo K, Nagahisa A.

Eur J Pharmacol. 1997 Mar 12;322(1):83-9.

PMID:
9088875
14.

Sensitivity of opioid receptor-like receptor ORL1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide.

Shimohigashi Y, Hatano R, Fujita T, Nakashima R, Nose T, Sujaku T, Saigo A, Shinjo K, Nagahisa A.

J Biol Chem. 1996 Sep 27;271(39):23642-5.

15.

Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor.

McLean S, Ganong A, Seymour PA, Bryce DK, Crawford RT, Morrone J, Reynolds LS, Schmidt AW, Zorn S, Watson J, Fossa A, DePasquale M, Rosen T, Nagahisa A, Tsuchiya M, Heym J.

J Pharmacol Exp Ther. 1996 May;277(2):900-8.

PMID:
8627572
16.

Tenidap, a structurally novel drug for the treatment of arthritis: antiinflammatory and analgesic properties.

Moore PF, Larson DL, Otterness IG, Weissman A, Kadin SB, Sweeney FJ, Eskra JD, Nagahisa A, Sakakibara M, Carty TJ.

Inflamm Res. 1996 Feb;45(2):54-61.

PMID:
8907585
17.

Cytochrome P-450scc-mediated oxidation of (20S)-22-thiacholesterol: characterization of mechanism-based inhibition.

Miao E, Joardar S, Zuo C, Cloutier NJ, Nagahisa A, Byon C, Wilson SR, Orme-Johnson WH.

Biochemistry. 1995 Jul 4;34(26):8415-21.

PMID:
7599132
18.

Aza-tricyclic substance P antagonists.

Lowe JA 3rd, Drozda SE, McLean S, Bryce DK, Crawford RT, Snider RM, Longo KP, Nagahisa A, Tsuchiya M.

J Med Chem. 1994 Sep 2;37(18):2831-40.

PMID:
7520943
19.

Antiinflammatory and analgesic activity of CP-96,345: an orally active non-peptide substance P receptor antagonist.

Nagahisa A, Kanai Y, Suga O, Taniguchi K, Tsuchiya M, Lowe JA 3rd, Hess HJ.

Regul Pept. 1993 Jul 2;46(1-2):440-3. No abstract available.

PMID:
7692561
20.

Non-specific activity of (+/-)CP-96,345 in models of pain and inflammation.

Nagahisa A, Asai R, Kanai Y, Murase A, Tsuchiya-Nakagaki M, Nakagaki T, Shieh TC, Taniguchi K.

Regul Pept. 1993 Jul 2;46(1-2):433-6. No abstract available.

PMID:
7692559
21.

Differential SAR of quinuclidine SP antagonists between rat and human-type receptors.

Snider RM, Longo KP, Zorn SH, Morrone J, Jackson ER, Nagahisa A, Kanai Y, Suga O, Nakagaki M, Drozda SE, et al.

Regul Pept. 1993 Jul 2;46(1-2):290-2. No abstract available.

PMID:
7692519
22.

Non-specific activity of (+/-)-CP-96,345 in models of pain and inflammation.

Nagahisa A, Asai R, Kanai Y, Murase A, Tsuchiya-Nakagaki M, Nakagaki T, Shieh TC, Taniguchi K.

Br J Pharmacol. 1992 Oct;107(2):273-5.

23.

Antiinflammatory and analgesic activity of a non-peptide substance P receptor antagonist.

Nagahisa A, Kanai Y, Suga O, Taniguchi K, Tsuchiya M, Lowe JA 3rd, Hess HJ.

Eur J Pharmacol. 1992 Jul 7;217(2-3):191-5.

PMID:
1330589
24.

The non-peptide tachykinin antagonist, CP-96,345, is a potent inhibitor of neurogenic inflammation.

Lembeck F, Donnerer J, Tsuchiya M, Nagahisa A.

Br J Pharmacol. 1992 Mar;105(3):527-30.

26.

Effect of P-450scc inhibitors on corticosterone production by rat adrenal cells.

Krueger RJ, Nagahisa A, Gut M, Wilson SR, Orme-Johnson WH.

J Biol Chem. 1985 Jan 25;260(2):852-9.

27.

Acetylenic mechanism-based inhibitors of cholesterol side chain cleavage by cytochrome P-450scc.

Nagahisa A, Spencer RW, Orme-Johnson WH.

J Biol Chem. 1983 Jun 10;258(11):6721-3.

Supplemental Content

Loading ...
Support Center